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THE SELFISH PATENT 
Bratislav Stankovic1 and Mirjana Stankovic2 
INTRODUCTION 
What is patentable in the United States, according to statute, dates 
back to the first United States Patent Act of 1790. The provisions of 
the U.S. patent code contain nothing specific about patenting living 
organisms; late nineteenth-century developments at the U.S. Patent 
and Trademark Office ("USPTO") both allowed3 and prohibited4 pat-
ents on living organisms. Fast forward a century, and the rapid ad-
vancements in biotechnology have led universities and companies 
conducting biotechnology research and development (R & D) to in-
creasingly depend upon patent protections. Part of this battle has in-
cluded the fight to expand the boundaries of what can be patented. 
Indeed, notwithstanding the recent temporary drop due to the eco-
nomic crisis, the global number of patent applications has been stead-
ily increasing. Based upon provisional date of the World Intellectual 
Property Organization (WIPO), 162,900 Patent Cooperation Treaty 
("PCT") international patent applications were filed in 2010.5 Of that 
total, it is estimated that 44,855 of those patent applications were filed 
1 Ph.D., University of Nebraska-Lincoln; J.D., University of Wisconsin-
Madison; Associate Dean, School of Law, University American College Skopje; 
Adjunct Professor, Loyola University Chicago Corboy School of Law. 
2 L.L.M., Chicago-Kent College of Law; L.L.M., Central European Univer-
sity, Budapest; Lecturer, University American College Skopje; Robert McNamara 
World Bank Fellow, Terry Sanford School of Public Policy, Duke University. 
3 In 1873, Louis Pasteur received a U.S. patent for "Manufacture of Beer 
and Yeast", in which yeast was deemed to be patentable subject matter. See U.S. 
Patent No. 141,072 claim 2 (filed July 22, 1873) ("Yeast, free from organic germs of 
disease, as an article of manufacture."). 
4 In 1889 the U.S. Commissioner of Patents rejected an application for a 
patent to cover a fiber identified in the needles of a pine tree. The Commissioner 
reasoned that a contrary result would permit "patents [to] be obtained upon the trees 
of the forest and the plants of the earth, which of course would be unreasonable and 
impossible." Ex parte Latimer, 1889 Dec. Comm'r. Pat. 123, 126, 46 O.G. 1638, 
1639. 
5 See International Patent Filings Recover in 2010, WORLD INTELLECTUAL 
PROP. 0RG (Feb. 9, 2011), 
http://www.wipo.int/pressroom/en/articles/2011/article_ 0004.html. 
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by U.S. applicants.6 According to the USPTO, 244,341 U.S. patents 
were granted in 2010.7 Approximately 1.75% of those patents (pre-
cisely 4,293) had one or more claims directed to DNA.8 
The recent biotechnological advances in genetic engineering, re-
combinant DNA, gene therapy, achieved potential for cloning animals 
and humans, and the isolation and manipulation of human embryonic 
stem cells (hESCs), easily capture the imagination. The prospects for 
their use in biomedical applications and personalized and regenerative 
medicine are seemingly without boundaries. Cutting and pasting 
genes into heterologous genomes has become a routine practice. Ani-
mals have been cloned through a variety of methods. Embryonic stem 
cells can be grown in Petri dishes (while maintaining pluripotency and 
preserving the ability to differentiate and form potentially any cell 
type that makes up the body), serving as a sort of repair system for the 
body. "Synthetic biology" offers the design and construction of new 
biological functions and systems not found in nature. The potential of 
these breakthrough biotechnological advances has made for great 
·"Patenting Life" op-ed headlines.9 However, the term "patenting life" 
is a misnomer. As "life" is not defined in the patent code, in this arti-
cle it is defined as the quality that distinguishes a vital and functional 
being from a dead body, and further, as one or more aspects of the 
process of living. 10 Life is a characteristic that distinguishes objects 
that have signaling and self-sustaining processes (i.e., living organ-
isms) from those that do not, either because they lack such functions 
and are classified as inanimate, or because such functions have ceased 
(through death). The fundamental principles on which a living system 
is based are: program; improvisation; compartmentalization; energy; 
regeneration; adaptability; and seclusion. 11 
The rapid developments in biotechnology have affected and sig-
nificantly challenged many areas of law, in particular patent law. In 
1980, the seminal decision of Diamond v. Chakrabarty, 12 in which the 
6 Id. 
7 U.S. Patent Statistics Chart Calendar Years 1963-2010, U.S. PATENT AND 
TRADEMARK OFFICE, http://www.uspto.gov/web/offices/ac/ido/oeip/taf/us_stat.htm 
(last updated Sept. 7, 2011, 10:16 AM). 
8 Mara Snyder & Bob Cook-Deegan, DNA PATENT DATABASE(Feb. 11, 
2011 ), http://dnapatents.georgetown.edu/resources/DPDStatistics201 O.pdf. 
9 Michael Crichton, Patenting Life, N.Y. TIMES, Feb. 13, 2007. at A23. 
10 Life Definition, M-W.coM, http://www.merriam-
webster.com/dictionary/life (last visited Oct. 24, 2011). 
11 Daniel E. Koshland Jr., The Seven Pillars of Life, 295 SCIENCE 2215 
(2002), available at http://www.sciencemag.org/content/295/5563/2215.full (last 
visited Oct. 24, 2011). 
12 Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980). The Court reasoned 
that Congress, in passing 35 U.S.C. § 101, did not distinguish between inanimate 
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U.S. Supreme Court ruled that living organisms are patentable subject 
matter, 13 arguably helped spark the biotechnology revolution of today. 
While the Chakrabarty opinion was directed toward the patentability 
of a genetically altered micro-organism, and not genes, it is often cited 
by proponents of gene patents for the mantra that "anything under the 
sun that is made by man" may be patented.14 In December 1982, the 
USPTO issued the first gene patent, which claimed the expression of 
genes for chorionic somatomammotropin, to the Regents of the Uni-
versity of California. 15 The primary examiner waited to examine the 
patent pending the outcome of Chakrabarty decision.16 
Since Chakrabarty, biotech companies and academic institutions 
have attempted to acquire ownership of gene sequences due to their 
potentially high economic value.17 As an indicator of the expansion 
of biotechnology patents, the number of utility patent applications 
filed with the USPTO increased 251%from1996 to 2010.18 Through 
2010, the number of issued US patents in the DNA Patent Database 
(containing at least one claim that includes a nucleic-acid-specific 
term "isolated" or "purified" -meaning not as it occurs in nature )was 
almost 58,000.19 Embryonic stem cell (ESC) research (and legal pro-
tection of the fruits of that research) emerged on the public scene in 
1998. The first patent with claims directed to human ESCs was issued 
in March 2001.20 In the biomedical field, patents are extremely valu-
able to companies, particularly small companies. Patents provide a 
means of securing investment income by establishing the company's 
preeminence in a particular area of (bio)technology. 
objects and living things as to patentable subject matter. The claimed genetically 
engineered bacteria, the method of producing them, and the process of using them 
were allowed. 
13 Id. At 318. 
14 Id. at 309 (quoting S. Rep. No. 1979, at 5 (1952); H.R. Rep. No. 1923, at 6 
(1952)). 
15 U.S. Patent No. 4,363,877 (filed Apr. 19, 1978). 
16 Matthew Rimmer, Genentech and the Stolen Gene: Patent Law and Pio-
neer Inventions, 5 B10-Sc1. L. REV. 198, 202 (2002). 
17 See Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial 
Incentives with Health Needs, 2 Hous. J. HEALTH L. & PoL'Y 65, 66 (2002) ("The 
patent on the human erythropoietin gene ... is worth more than $1.5 billion a year 
.... "). 
18 U.S. Patent Statistics Chart, UNITED STATES PATENT AND TRADEMARK 
OFFICE, http://www.uspto.gov/web/offices/ac/ido/oeip/taf/us_stat.htm (last updated 
Sept. 7, 2011 ). There were 490,226 utility patent applications in 2010, as opposed to 
195,187 such applications in 1996. 
19 Snyder & Cook-Deegan, supra note 8. 
20 U.S. Patent No. 6,200,806 (filed June 26, 1998). 
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Research with and patentability of genes, transgenic organisms, 
and stem cells makes for headline news and is at the center of a myr-
iad of ethical, religious, metaphysical, and political debates.21 Be-
cause the moral and legal justifications are not identical, it is possible 
for a legal decision to be immoral although consistent with legal 
precedent and procedure. Contributing to that debate and enriching 
the conversation, this article addresses some of the issues surrounding 
patentability of inventions related to DNA, genes, stem cells, trans-
genic organisms and, in general, related to living matter. This article 
reflects on the role of "patents on life inventions" in society, and dis-
cusses the intersection of legal, scientific, ethical, and moral issues 
that surround the topic. It also analyzes empirical case studies to ad-
dress both sides of the anti-commons debate and to determine if the 
fear related to this effect in the biotechnology field is actually justi-
fied, or is largely over-estimated. In addition, this article focuses on 
four common myths and perceptions related to controversial biotech-
nology inventions and their protection with patents, and then com-
pares these myths and perceptions to the empirical evidence. 
I. MYTH OR REALITY NO. 1: ISOLATED HUMAN GENES 
ARE MERE DISCOVERIES OR CREATIONS OF NATURE, 
AND ARE THUS UNPATENTABLE SUBJECT MATTER. 
The patentability of life and human subject matter has been de-
bated over the years. One major myth regarding patents on living or-
ganisms is that the first "patent on life" was awarded in 1980 in Chak-
rabarty .22 However, Ananda Chakrabarty was beaten by over a cen-
tury; in 1873 Louis Pasteur received a U.S. patent for a living organ-
ism. In the granted patent for "Manufacture of Beer and Yeast," yeast 
21 See generally, George J. Annas, Life Forms, the Law and Profits, THE 
HASTINGS CENTER REPORT, (Oct. 1978), pp. 21-22; MICHAEL BELLOMO, THE STEM 
CELL DIVIDE: THE FACTS, THE FICTION, AND THE FEAR DRIVING THE GREATEST 
SCIENTIFIC, POLITICAL, AND RELIGIOUS DEBATE OF OUR TIME (2006); LEO FURCHT & 
WILLIAM HOFFMAN, THE STEM CELL DILEMMA: BEACONS OF HOPE OR HARBINGERS OF 
DOOM? (2008); SUZANNE HOLLAND ET AL., THE HUMAN EMBRYONIC STEM CELL 
DEBATE: SCIENCE, ETHICS, AND PUBLIC POLICY (2001); KR:ISET R. MONROE ET AL., 
FUNDAMENTALS OF THE STEM CELL DEBATE: THE SCIENTIFIC, RELIGIOUS, ETHICAL AND 
POLITICAL ISSUES (2007); LARS 0STNOR, STEM CELLS, HUMAN EMBRYOS AND ETHICS: 
INTERDISCIPLINARY PERSPECTIVES (2008); JEREMY R:rFKIN, THE BIOTECH CENTURY: 
HARNESSING THE GENE AND REMAKING THE WORLD (1998); Eric D. Zard, Patentabil-
ity of Human Genetic Information: Exploring Ethical Dilemmas Within the Patent 
Office and Biotechnology's Clash With the Public Good, 6 U. ST. THOMAS L.J. 486 
(2009). 
22 Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
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was deemed to be patentable subject matter.23 Yet, patentability is not 
without its limits. To date, the USPTO has set boundaries on pat-
entability of living matter, expressly excluding patentability of human 
beings, human embryos, and human/animal chimera.24 
Each of the patentability requirements under Title 35 of the U.S. 
Code - patentable subject matter, novelty, usefulness, and non-
obviousness - could be raised with respect to gene patents.25 How-
ever, courts have upheld patents on isolated and purified natural sub-
stances like isolated gene sequences.26 
The question of whether genes are patentable subject matter under 
35 U.S.C. § 10127 is presently being hotly debated, most recently in 
the Myriad "gene patents" case.28 The Federal Circuit reversed an 
earlier district court decision that invalidated gene patents directed to 
BRCAl and BRCA2.29 On March 29, 2010, Judge Sweet of the 
United States Federal District Court for the Southern District of New 
York issued a lengthy opinion in which he characterized "DNA" and 
"isolated DNA" as, respectively, the physical manifestation of DNA 
and as "a segment of DNA nucleotides" existing separate from the 
cell and other proteins.30 However, on July 29, 2011, the Federal Cir-
cuit reversed the decision of the district court on the major substantive 
issue and ruled that isolated DNA molecules do constitute patent eli-
23 U.S. Patent No. 141,072 (Filed July 22, 1873) (claiming "Yeast, free from 
organic germs of disease, as an article of manufacture"). 
24 See generally, Sean M. Coughlin, The Newman Application and the 
USPTO's Unnecessary Response: Patentability of Humans and Human Embryos, 5 
CHI.-KENT J. INTELL. PROP. 90, 91 (2006). 
25 See Andrews, supra note 17, at 70-72 (arguing that the useful properties of 
the gene could be classified as natural, inherent properties of genes themselves and 
stating that the computer sequencing techniques could make patenting genes obvious, 
and arguing that a gene may not be novel enough after it is removed from an affected 
individual). 
26 See Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. Cir. 
2003); Bio-Tech. Gen. Corp. v. Genentech, Inc., 267 F.3d 1325 (Fed. Cir. 2001). 
27 35 U.S.C. § 101 (2010) ("Whoever invents or discovers any new and 
useful process, machine, manufacture, or composition of matter, or any new and 
useful improvement thereof, may obtain a patent therefore, subject to the conditions 
and requirements of this title."). 
28 Ass'n for Molecular Pathology v. USPTO (Myriad), 653 F.3d 1329 (Fed. 
Cir 2011), rev'g, 702 F.Supp.2d 181 (S.D.N.Y. 2010). 
29 Id, at 1353 ("We therefore reject the district court's unwarranted categori-
cal exclusion of isolated DNA molecules."). 
30 Ass'n for Molecular Pathology v. USPTO, 702 F.Supp.2d 181, 217 
(S.D.N.Y 2010), rev'd, 653 F.3d 1329 (Fed. Cir. 2011). The district court considered 
whether the claimed compositions and methods constitute statutory subject matter or 
fell under the judicially created products of nature exception to patentable subject 
matter. Id. at 184-86. 
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gible subject matter.31 Still, this fight seems far from over, perhaps 
with additional appeals yet to come. 
The biological and legal definitions of DNA differ, but the reality 
is the same;32 isolated DNA does not exist in nature. Broadly defining 
35 U.S.C. § 101, the Supreme Court in Chakrabarty distinguished 
between products of nature, whether living or not, and a non-naturally 
occurring manufacture or composition of matter-"a product of hu-
man ingenuity 'having a distinctive name, character [and] use.' "33 
The district court in Myriad concluded that because patentable subject 
matter must be markedly different from a product of nature, the 
claimed isolated DNA was not markedly different from native DNA 
and, therefore was not patentable under section 101.34 However, that 
reasoning was not accepted by the Federal Circuit. 35 Indeed, the Su-
preme Court has consistently construed§ 101 broadly, explaining that 
"[i]n choosing such expansive terms ... modified by the comprehen-
sive 'any,' Congress plainly contemplated that the patent laws would 
be given wide scope."36 
To be patentable, an invention must be a "manufacture," obtained, 
for example, through "the production of articles for use from raw or 
prepared materials by giving to these materials new forms, qualities, 
properties, or combinations, whether by hand-labor or by machin-
ery."37 Even if the product were merely extracted without change, 
31 Ass'nfor Molecular Pathology, 653 F.3d at 1334. The Federal Circuit also 
ruled that methods relating to the screening for potential cancer therapeutics are, 
likewise, patent eligible subject matter. Id, However, the Federal Circuit affirmed the 
decision of unpatentability for method claims reciting merely steps of "comparing" or 
"analyzing" DNA sequences, on the grounds that these claims failed the machine or 
transformation test from Bilski. Id, 
32 Biologists will generally agree that "DNA" is a double helix molecule, 
consisting of an ti parallel strands in which the nucleotide units are linked by 5 '-3' 
phosphodiester bonds. DNA is the genetic material in all known organisms and many 
viruses. A "gene" is a DNA segment that encodes the information for producing a 
polypeptide chain; it includes other regions as well. Cf GRAY'S ANATOMY 48-50 
(Lawrence H. Bannister et al. eds., Churchill Livingstone 38th ed. 1995); THE 
AMERICAN HERITAGE MEDICAL DICTIONARY 159 (Margery S. Berube et al. eds., 2008). 
33 Diamond v. Chakrabarty, 447 U.S. 303, 309-10 (1980) (citing Hartranft v. 
Wiegmann, 121 U.S. 609 (1887)). The Court has previously stated that "[t]he 'mat-
ter' of which patentable new and useful compositions are composed necessarily in-
cludes naturally existing elements and materials." Merck & Co. v. Olin Mathieson 
Chem. Corp., 253 F.2d 156, 162 (4th Cir. 1958). 
34 Ass'nfor Molecular Pathology, 702 F.Supp.2d at 232. 
35 See Ass'nfor Molecular Pathology, 653 F.3d at 1351. 
36 Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (quoting Chakrabarty, 447 
U.S. at 308). 
37 Chakrabarty, 447 U.S. at 308. 
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still, "there is no rule that such products are not patentable."38 To dif-
fer in kind, the product must have "a new utility in which invention 
may rest."39 As an example, an alkaloid cephalomannine, separated 
and purified from the tissue of plants and found to be useful in caus-
ing remission of leukemic tumors in mice, was deemed patent-eligible 
subject matter.40 Likewise, an isolated gene that was previously uni-
dentified and unknown, and was found to possess advantageous char-
acteristics was patentable.41 The process of creating a product of high 
diagnostic and commercial value from an isolated, naturally occurring 
gene, is not a "mere advance in the degree of purity of a known prod-
uct."42 An isolated gene, although derived from a naturally occurring 
gene, is a synthetic product made by man. In the process of isolating a 
gene, copies of the naturally occurring gene are degraded or elimi-
nated and the synthetic copies of that gene are further purified from 
other nucleic acids, proteins, and other cellular components. Alterna-
tively, synthetically produced nucleotides could be used to form a 
copy of a target DNA sequence in vitro. The result is a man-made 
synthetic DNA product that is identical to the template DNA with 
regards to information stored for the use of polypeptide production .. 
For patentability purposes, the new product is unique. The origi-
nal (naturally occurring) DNA sequences are not only isolated, but 
they are manipulated, synthetically copied, and/or amplified, thereby 
creating an isolated, man-made DNA sequence that is based on the 
naturally occurring sequence. Additionally, an isolated gene does not 
occur naturally since all naturally occurring genes are integrated 
within the genome of a cell43 . While the function of a specific DNA 
sequence in a cell in its natural state is to code for a specific polypep-
tide, the use of an isolated gene is different from the use of a naturally 
occurring gene in the cell. Therefore, when a gene is isolated from a 
chromosome in a cell, it cannot be naturally regulated, meaning it 
cannot perform its natural function. In addition, the function of a gene 
38 Merck, 253 F.2d at 163 (confirming the patentability of isolated vitamin 
B12). 
39 Id. at 164. 
40 U.S. Patent No. 4,206,221 (filed Jan 3, 1979). 
41 Merck, 253 F.2d at 162-3. For example, BRCAl and BRCA2 genes can be 
used as diagnostic tools to detect carriers with mutations. See Ass'nfor Molecular 
Pathology, 653 F.3d at 1335. 
42 Merck, 253 F.2d at 164. 
43 Using molecular biology techniques, the polynucleotide sequence of a 
gene is removed from the rest of the genome and is then manipulated in vitro. That 
makes the gene "isolated" (from the rest of the genome). 
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heavily depends on its position in the genome;44 it is precisely the fact 
that a gene is isolated from the genome of the cell that makes the gene 
patentable. 
Genes have a double nature, serving as both chemical substances 
and as physical carriers of information.45 A patent over a single gene 
grants a monopoly over the use of the isolated gene, but not over the 
information that it carries or the principle of how the information is 
carried. Since a gene not only carries information, but is also a chemi-
cal compound, it is subject to the same requirements imposed upon 
the chemical arts under Title 35 of the U.S. Code.46 Therefore, genes 
. bl b" 47 constitute patenta e su ~ect matter. 
Globally, the Trade-Related Aspects of Intellectual Property 
Rights Agreement ("TRIPS") permits the patentability of genetic 
material.48 Article 27.1 of the TRIPS Agreement clearly states: "pat-
ents shall be available for any inventions, whether products or proc-
esses, in all fields of technology, provided that they are new, involve 
an inventive step and are capable of industrial application."49 Thus, 
TRIPS does not prohibit obtaining patents on genetic material. 
Lastly, a few words about the "lawyer's trick" raised by Judge 
Sweet in Myriad.50 It is deja vu. Judge Sweet explained that isolat-
ing a gene to make it patentable is "a 'lawyer's trick' that circumvents 
the prohibition on the direct patenting of the DNA in our bodies but 
44 NEILA CAMPBELL ET AL., BIOLOGY 296 (5th ed. 1999) (changes in the 
gene's position on a chromosome or changes in its copy number or in its sequence are 
the causes for several disease). 
45 See Ass'n for Molecular Pathology v. USPTO, 702 F.Supp.2d 181, 228 
(S.D.N.Y. 2010). 
46 35 U.S.C. § 101 (2010). 
47 See Ass'n for Molecular Pathology v. USPTO, 653 F.3d 1329, 1334, 1355 
(Fed. Cir. 2011) (reversing a district court's ruling that isolated DNA molecules are 
unpatentable) ("[T]he PTO has issued patents directed to DNA molecules for almost 
thirty years. In the early 1980s, the Office granted the first human gene patents. It is 
estimated that the PTO has issued 2,645 patents claiming 'isolated DNA' over the 
past twenty-nine years, and that by 2005, had granted 40,000 DNA-related patents 
covering, in non-native form, twenty percent of the genes in the human genome.") 
(citations omitted). Cf Diamond v. Chakrabarty, 447 U.S. 303, 308-18 (1980) (hold-
ing that a live, human-made micro-organism is patentable subject matter because it 
constitutes a "manufacture" or "composition of matter" within the meaning of 35 
U.S.C. § 101.). See generally Eric J. Rogers, Can You Patent Genes? Yes and No, 93 
J. PAT. & TRADEMARK OFF. Soc'Y 19 (2010). 
48 Agreement on Trade-Related Aspects of Intellectual Property Rights art. 
27.1, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organiza-
tion, Annex IC, 1869 U.N.T.S. 299 [hereinafter TRIPS Agreement]. 
49 Id. 
50 Ass'nfor Molecular Pathology, 702 F. Supp.2d at 185. 
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which, in practice, reaches the same result."51 However, one hundred 
years ago, in a decision regarding the patentability of purified adrena-
line, Judge Learned Hand ruled: 
Takamine was the first to make it available for any use by re-
moving it from the other gland-tissue in which it was found, 
and, while it is of course possible logically to call this a purifi-
cation of the principle, it became for every practical purpose a 
new thing commercially and therapeutically. That was a good 
ground for a patent. 52 
Similarly, in a 2010 speech at the BIO International Convention, 
USPTO Director David Kappas stated: 
To say that an isolated, purified DNA sequence is a product of 
nature is like saying a silicon wafer of 99.9999% purity used in 
the microelectronics industry, which I am very familiar with, is 
a product of nature because, of course, silicon is found in the 
Earth's crust. Of course, wafer grade silicon is not found in na-
ture, we all know that. It requires an extremely intricate and 
extremely laborious purification process.53 
The fact that a substance exists in nature does not mean that a pu-
rified, isolated, or otherwise refined version of that substance is a 
product of nature. Genes are statutory subject matter.54 It is unclear 
why DNA and Taxol (for example), both naturally occurring mole-
cules and physical embodiments of the laws of nature, should be 
treated differently once isolated.55 
II. MYTH OR REALITY NO. 2: PATENTS ON 
BIOTECHNOLOGY INVENTIONS STIFLE RESEARCH. 
Within the biotechnology and biomedical communities, scientists 
and researchers alike have argued that the proliferation of patents in 
51 Id. 
52 Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (S.D.N.Y. 1911). 
53 David Kappos, Director, USPTO, Speech at the BIO International Con-
vention (2010). 
54 See supra notes 37-47 and accompanying text. 
55 Taxol, isolated from yew trees, is patented. U.S. Patent No. 5,451,392 
(filed Sept. 19, 1995). Other cases confirm the patentability of purified compounds. 
See, e.g., Scripps Clinic and Research Found. v. Genentech, Inc., 
666 F. Supp. 1379, 1389 n.6 (N.D. Cal. 1987) (purified Factor VIII); In re Kratz, 592 
F.2d 1169, 1175 (C.C.P.A. 1979) (strawberry fragrance). 
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the area of genetics has severely inhibited genetic research as well as 
patient care.56 Due to rising transactional costs and the fear of litiga-
tion associated with patents, researchers are concerned that excessive 
patenting of basic or upstream research will greatly inhibit innovation 
of downstream technologies.57 As discussed below, a number of em-
pirical studies have been conducted to determine whether over-
patenting of biotechnology research tools and genetic inventions have 
detrimentally affected downstream innovation. 
Opponents of patenting biotechnology inventions such as genes, 
stem cells and research tools argue that patent ownership of research 
tools increases transaction costs and impedes scientific progress.58 The 
opponents contend that an anticommons effect could have a disastrous 
impact on biomedical research. Because discoveries in biomedical 
research are directly related to human health, the potential exists that 
people may die if certain life-saving studies are blocked. 59 The oppo-
nents further argue that anticommons may not only stem from the 
patenting of broad claims, but from exclusively licensing the research 
tools to a single company or university, thereby essentially eliminat-
ing competitive products.60 Researchers list Myriad Genetics, BRCAl 
and BRCA2 genes, hemochromatosis, and Canavan disease as con-
tributing to this anticommons.61 Some stem cell scientists believe that 
"frivolous and overly broad patents ... mock science and muck up pat-
enting. "62 A closer look reveals that most of the focus over the past 
56 Larry Greenemeier, Case Studies Reveal that Patents Can Hinder Genetic 
Research and Patient Care, SCIENTIFIC AMERICAN (Apr. 16, 2010), 
http://www.scientificamerican.com/article.cfm?id=gene-patent. 
57 Michael A. Heller, The Tragedy of the Anticommons: Property in the 
Transition from Marx to Markets, 111 HARV. L. REV. 621, 624 (1998). 
58 John Stiglitz& John Sulston, The Case Against Gene Patents, WALL ST. J., 
Apr. 16, 2010, at A19 (arguing that gene patents not only prevent the use of knowl-
edge but also impede scientific research). 
59 Ornid E. Khalifeh, The Gene Wars: Science, the Law and the Human 
Genome 25-26 (Oct. 2009) (unpublished paper, Chapman University School of Law), 
available at 
\http://works.bepress.com/cgi/viewcontent.cgi?article=lOOl&context=ornid_khalifeh. 
60 See Greenemeier, supra note 56, at 1 ("The problem is not with the patents 
themselves but rather when overly broad patents are exclusively licensed to a single 
company or university .... "). 
61 Ronald Bailey, The Tragedy of the Anticommons: Do patents actually 
impede innovation?, REASON.COM (Oct. 2, 2007), 
http://reason.com/archives/2007 /10/02/the-tragedy-of-the-anticommons (presenting 
certain examples given by researchers and scientists as to the existence of an anti-
commons due to over proliferation of patents in the biotechnology field). 
62 Don Moyer, Frivolous and Overly Broad Patents, SCIENCE PATENTING 
NEXUS EXPLORED (July 28, 2008, 10:16 AM), http://science-
patenting.blogspot.com/2008/07 /frivolous-and-overly-broad-patents.html. 
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few years, in regards to the tragedy of the anticommons, has centered 
on the BRCA gene patents.63 Because BRCA/Myriad is the only high-
profile controversy that has illustrated the potential consequences of 
patenting genes, the problem may be largely over-exaggerated.64 Ac-
cordingly, it is important to analyze empirical data on both sides of 
the research stifling/anticommons debate to reach a more accurate 
conclusion on the issue, and to determine if the fear related to this 
effect in the biotechnology field is actually justified, or is largely 
over-estimated. 
To date, the USPTO has issued over 2,000 patents directed to 
stem cell technologies, and over 400 patents directed to embryonic 
stem cell ("ESC") technologies. Three pioneer ESC patents with 
broad claims were issued to James Thomson from the University of 
Wisconsin, which he assigned to the Wisconsin Alumni Research 
Foundation (W ARF).65 To escape the reach of WARF' s patents, some 
organizations chose to conduct human embryonic stem cell research 
outside of the U.S.66 There was concern in the stem cell community 
about how the availability and cost of licenses would affect the com-
mercialization of stem cell therapeutics.67 As discussed below, how-
ever, research which looks at the past decade shows this criticism may 
be un-founded, based upon the scope of admirable research advances 
63 See Timothy Caulfield et al., Evidence and Anecdotes: An Analysis of 
Human Gene Patenting Controversies, 24 NATURE BIOTECHNOLOGY 1091 (2006) 
(illustrating that the subject of Myriad Genetics and BRCAl and BRCA2 was refer-
enced in over 470 major policy documents since 2002). 
64 See Bailey, supra note 61 (Claire Driscoll, Director of the National Human 
Genome Research Institute' s Technology Transfer Office, voiced her opinion on the 
link between biomedical research and the tragedy of the anticommons at a presenta-
tion in 2007: "In my 10 or 15 years of doing this [technology transfer], I hear the 
same five examples or six examples repeated over and over. We can all name them 
by heart: BRCAl and [BRCA]2; Myriad Genetics; hemochromatosis; Canavan dis-
ease. It's the same ones. Are there any new ones? Is it getting worse, or is it just 
these few that are exceptional? I really think there are only a few, and I think it's the 
same ones over and over again."). 
65 Aurora Plomer et al., Challenges to Human Embryonic Stem Cell Patents, 
2 CELL 13, 13 (2008). All three patents have been subjected to reexamination. See 
infra, note 66. 
66 Lisa A. Haile & Stacy Taylor, USPTO Rejects Broad Human Stem Cell 
Patents, DLA PIPER (Apr. 5, 2007), 
http://www.dlapiper.com/files/upload/10146%2001 %20Stem%20Cell %20Patent%20 
Alert_ vlsj_070405.html ("Even so, a number of organizations are choosing to con-
duct their embryonic stem cell research programs outside the United States, a decision 
attributed by some to a desire to avoid the reach of the WARF patents."). 
67 Id. (WARF has come under extensive criticism from the stem cell com-
munity for its insistence on license terms that many see as sufficiently onerous to 
slow the progress of embryonic stem cell research."). 
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few years, in regards to the tragedy of the anticommons, has centered 
on the BRCA gene patents.63 Because BRCA/Myriad is the only high-
profile controversy that has illustrated the potential consequences of 
patenting genes, the problem may be largely over-exaggerated.64 Ac-
cordingly, it is important to analyze empirical data on both sides of 
the research stifling/anticommons debate to reach a more accurate 
conclusion on the issue, and to determine if the fear related to this 
effect in the biotechnology field is actually justified, or is largely 
over-estimated. 
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stem cell technologies, and over 400 patents directed to embryonic 
stem cell ("ESC") technologies. Three pioneer ESC patents with 
broad claims were issued to James Thomson from the University of 
Wisconsin, which he assigned to the Wisconsin Alumni Research 
Foundation (W ARF).65 To escape the reach of W ARF's patents, some 
organizations chose to conduct human embryonic stem cell research 
outside of the U.S.66 There was concern in the stem cell community 
about how the availability and cost of licenses would affect the com-
mercialization of stem cell therapeutics.67 As discussed below, how-
ever, research which looks at the past decade shows this criticism may 
be un-founded, based upon the scope of admirable research advances 
63 See Timothy Caulfield et al., Evidence and Anecdotes: An Analysis of 
Human Gene Patenting Controversies, 24 NATURE BIOTECHNOLOGY 1091 (2006) 
(illustrating that the subject of Myriad Genetics and BRCAI and BRCA2 was refer-
enced in over 470 major policy documents since 2002). 
64 See Bailey, supra note 61 (Claire Driscoll, Director of the National Human 
Genome Research Institute' s Technology Transfer Office, voiced her opinion on the 
link between biomedical research and the tragedy of the anticornrnons at a presenta-
tion in 2007: "In my 10 or 15 years of doing this [technology transfer], I hear the 
same five examples or six examples repeated over and over. We can all name them 
by heart: BRCAl and [BRCA]2; Myriad Genetics; hernochrornatosis; Canavan dis-
ease. It's the same ones. Are there any new ones? Is it getting worse, or is it just 
these few that are exceptional? I really think there are only a few, and I think it's the 
same ones over and over again."). 
65 Aurora Plorner et al., Challenges to Human Embryonic Stem Cell Patents, 
2 CELL 13, 13 (2008). All three patents have been subjected to reexamination. See 
infra, note 66. 
66 Lisa A Haile & Stacy Taylor, USPTO Rejects Broad Human Stem Cell 
Patents, DLA PIPER (Apr. 5, 2007), 
http://www.dlapiper.com/files/upload/10146%2001 %20Stern%20Cell %20Patent%20 
Alert_ v 1 sj_070405 .html ("Even so, a number of organizations are choosing to con-
duct their embryonic stern cell research programs outside the United States, a decision 
attributed by some to a desire to avoid the reach of the WARF patents."). 
67 Id. (WARP has come under extensive criticism from the stern cell com-
munity for its insistence on license terms that many see as sufficiently onerous to 
slow the progress of embryonic stern cell research."). 
78 JOURNAL OF LAW, TECHNOLOGY & THE INTERNET [Vol. 3:1 
in the embryonic stem cell field, accompanied by substantial patenting 
activity. 
Surveyed Canadian stem cell researchers were divided about the 
impact of patents on the research environment. Even though there was 
minimal evidence of problems associated with patenting and commer-
cialization on research, the surveyors were not quick to dismiss the 
concerns associated with patents and research commercialization. 
Their perception was that patents can limit the ability of researchers to 
carry out important research, increase secrecy among researchers, 
unduly increase the cost of doing research, reduce the researchers' 
ability to use patented technologies, increase dependence on industry, 
and decrease public trust in science. 68 
A comprehensive empirical study commissioned by the National 
Academy of Sciences in 2003 analyzed the impact on downstream 
innovation due to the patenting of upstream, basic research tools. 69 
The study found almost no evidence of a breakdown in negotiations 
between two parties due to a patent research tool leading to an R&D 
project's cessation.70 There were only a few cases in which the trans-
actional costs due to patents may have pre-empted some researchers 
from pursuing a given project.71 Additionally, no anticommons effect 
was created due to patents on expressed sequence tags.72 The study 
found that restricted access to research tools because of a patent 
holder's exclusive license agreement could limit the exploitation of 
68 Timothy Caulfield et al., Patents, Commercialization and the Canadian 
Stem Cell Research Community, 3(4) REGENERATIVE MED. 483, 485-86 (2008), avail-
able at http://www.futuremedicine.com/doi/pdf/10.2217/17460751.3.4.483? (twelve 
out of twenty-five researchers surveyed stated that patents had a negative impact on 
the research environment). 
69 John P. Walsh et al., Science and the Law: Working Through the Patent 
Problem, 299 SCIENCE 1021 (2003) (conducting 70 interviews with IP attorneys, 
business managers, scientists from 10 pharmaceutical firms and 15 biotech firms, 
researchers and technology transfer officers from 6 universities, patent lawyers, and 
government and trade association personnel). 
70 John P. Walsh et al., Effects of Research Tool Patents and Licensing on 
Biomedical Innovation, in PATENTS IN THE KNOWLEDGE-BASED ECONOMY 285 
(Wesley M. Cohen and Stephen A Merrill eds., 2003). 
71 Id. at 298 (When 55 of the respondents addressed the issue of project 
cessation, 54 of them could not recall cancelling a specific project due to patents over 
research tools. "One biotechnology executive stated: 'I am hard pressed to think of a 
piece ofresearch that we haven't done because of blocked access to a research tool. 
We have dropped products because others were ahead in proprietary position, but that 
is different.' "). 
72 Id. at 299 ("Our respondents suggested that this has not occurred."). 
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research tools by other parties.73 However, asserting exclusivity could 
confer a benefit by increasing the incentives to do research to discover 
the target first and then further invest in its research.74 
In 2005, responding to Madey v. Duke University,75 the National 
Academy of Sciences commissioned a study of bench scientists to 
determine the impact of patents and licensing on access to biomedical 
research tools.76 This study found that the existence of patents did not 
dissuade academic researchers from pursuing certain projects.77 Only 
3% of the respondents abandoned a project because too many patents 
were covering their research tools. 78 
A more recent empirical analysis of major stem cell patent cases 
focused on whether an anticommons effect in this field was formed 
after the Madey decision.79 The main finding was that the post-Madey 
fears of massive litigation against academic institutions had not been 
realized. Contrary to popular belief, "the rate of litigation to issued 
patents in the categories studied is extremely small, which calls into 
question the claim that a large amount of litigation is causing an anti-
commons."80 In fact, the number of litigated stem cell cases from 
1986 to 2007 actually decreased each year after 1997. 81 
73 Id. at 331 (finding that "restricted access to some upstream discovery ... 
has not yet impeded biomedical innovation significantly, but our interviews and prior 
cases suggest that the prospect exists and ongoing scrutiny is warranted.") .. 
74 Id. at 310 ("[T]his right to assert exclusivity may confer a benefit in the 
form of increasing the incentives to do the research to discover the target to begin 
with."). 
75 Madey v. Duke Univ., 307 F.3d 1351, 1362 (Fed. Cir. 2002) (holding that 
university research did not fall under the common law experimental use exception 
because it was not performed "for amusement, to satisfy idle curiosity, or for strictly 
philosophical inquiry," but as part of the university's legitimate business objective"). 
76 John P. Walsh et al., View from the Bench: Patents and Material Trans-
fers, 309 SCIENCE 2002, 2002 (2005) (study based upon 414 received responses from 
biomedical researchers in academia, industry, government, and non-profit sectors). 
77 Id. ("Thus, of 381 academic scientists, even including the 10% who 
claimed to be doing drug development or related downstream work, none were 
stopped by the existence of third-party patents, and even modifications or delays were 
rare."). 
78 Id. at 2003 ("only 3% of respondents reported stopping a project in the 
past 2 years because of a patent"). 
79 Ann E. Mills & Patti M. Tereskerz, Empirical Analysis of Major Stem Cell 
Patent Cases: The Role of Universities, 28 NATURE BIOTECHNOLOGY 325 (2010). 
This study analyzed the parties in 67 patent cases involving 23 patents related to stem 
cells filed between 1986 and 2007. Out of the 67 cases, 7 involved university plain-
tiffs, while only 1 out of the 89 total defendants in those cases was a university. Id. at 
326. 
80 Id. at 327. 
81 Id. at 325 figure 1. 
78 JOURNAL OF LAW, TECHNOLOGY & THE INTERNET [Vol. 3:1 
in the embryonic stem cell field, accompanied by substantial patenting 
activity. 
Surveyed Canadian stem cell researchers were divided about the 
impact of patents on the research environment. Even though there was 
minimal evidence of problems associated with patenting and commer-
cialization on research, the surveyors were not quick to dismiss the 
concerns associated with patents and research commercialization. 
Their perception was that patents can limit the ability of researchers to 
carry out important research, increase secrecy among researchers, 
unduly increase the cost of doing research, reduce the researchers' 
ability to use patented technologies, increase dependence on industry, 
and decrease public trust in science. 68 
A comprehensive empirical study commissioned by the National 
Academy of Sciences in 2003 analyzed the impact on downstream 
innovation due to the patenting of upstream, basic research tools. 69 
The study found almost no evidence of a breakdown in negotiations 
between two parties due to a patent research tool leading to an R&D 
project's cessation.70 There were only a few cases in which the trans-
actional costs due to patents may have pre-empted some researchers 
from pursuing a given project.71 Additionally, no anticommons effect 
was created due to patents on expressed sequence tags. 72 The study 
found that restricted access to research tools because of a patent 
holder's exclusive license agreement could limit the exploitation of 
68 Timothy Caulfield et al., Patents, Commercialization and the Canadian 
Stem Cell Research Community, 3(4) REGENERATIVE MED. 483, 485-86 (2008), avail-
able at http://www.futuremedicine.com/doi/pdf/10.2217 /17460751.3.4.483? (twelve 
out of twenty-five researchers surveyed stated that patents had a negative impact on 
the research environment). 
69 John P. Walsh et al., Science and the Law: Working Through the Patent 
Problem, 299 SCIENCE 1021 (2003) (conducting 70 interviews with IP attorneys, 
business managers, scientists from 10 pharmaceutical firms and 15 biotech firms, 
researchers and technology transfer officers from 6 universities, patent lawyers, and 
government and trade association personnel). 
70 John P. Walsh et al., Effects of Research Tool Patents and Licensing on 
Biomedical Innovation, in p ATENTS IN THE KNOWLEDGE-BASED ECONOMY 285 
(Wesley M. Cohen and Stephen A Merrill eds., 2003). 
71 Id. at 298 (When 55 of the respondents addressed the issue of project 
cessation, 54 of them could not recall cancelling a specific project due to patents over 
research tools. "One biotechnology executive stated: 'I am hard pressed to think of a 
piece ofresearch that we haven't done because of blocked access to a research tool. 
We have dropped products because others were ahead in proprietary position, but that 
is different.' "). 
72 Id. at 299 ("Our respondents suggested that this has not occurred."). 
2011] THE SELFISH PATENT 79 
research tools by other parties.73 However, asserting exclusivity could 
confer a benefit by increasing the incentives to do research to discover 
the target first and then further invest in its research.74 
In 2005, responding to Madey v. Duke University,75 the National 
Academy of Sciences commissioned a study of bench scientists to 
determine the impact of patents and licensing on access to biomedical 
research tools.76 This study found that the existence of patents did not 
dissuade academic researchers from pursuing certain projects.77 Only 
3% of the respondents abandoned a project because too many patents 
were covering their research tools.78 
A more recent empirical analysis of major stem cell patent cases 
focused on whether an anticommons effect in this field was formed 
after the Madey decision.79 The main finding was that the post-Madey 
fears of massive litigation against academic institutions had not been 
realized. Contrary to popular belief, "the rate of litigation to issued 
patents in the categories studied is extremely small, which calls into 
question the claim that a large amount of litigation is causing an anti-
commons."80 In fact, the number of litigated stem cell cases from 
1986 to 2007 actually decreased each year after 1997.81 
73 Id. at 331 (finding that "restricted access to some upstream discovery ... 
has not yet impeded biomedical innovation significantly, but our interviews and prior 
cases suggest that the prospect exists and ongoing scrutiny is warranted.") .. 
74 Id. at 310 ("[T]his right to assert exclusivity may confer a benefit in the 
form of increasing the incentives to do the research to discover the target to begin 
with."). 
75 Matley v. Duke Univ., 307 F.3d 1351, 1362 (Fed. Cir. 2002) (holding that 
university research did not fall under the common law experimental use exception 
because it was not performed "for amusement, to satisfy idle curiosity, or for strictly 
philosophical inquiry," but as part of the university's legitimate business objective"). 
76 John P. Walsh et al., View from the Bench: Patents and Material Trans-
fers, 309 SCIENCE 2002, 2002 (2005) (study based upon 414 received responses from 
biomedical researchers in academia, industry, government, and non-profit sectors). 
77 Id. ("Thus, of 381 academic scientists, even including the 10% who 
claimed to be doing drug development or related downstream work, none were 
stopped by the existence of third-party patents, and even modifications or delays were 
rare."). 
78 Id. at 2003 ("only 3% of respondents reported stopping a project in the 
past 2 years because of a patent"). 
79 Ann E. Mills & Patti M. Tereskerz, Empirical Analysis of Major Stem Cell 
Patent Cases: The Role of Universities, 28 NATURE BIOTECHNOLOGY 325 (2010). 
This study analyzed the parties in 67 patent cases involving 23 patents related to stem 
cells filed between 1986 and 2007. Out of the 67 cases, 7 involved university plain-
tiffs, while only 1 out of the 89 total defendants in those cases was a university. Id. at 
326. 
80 Id. at 327. 
81 Id. at 325 figure 1. 
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Proponents of gene patenting state that there is little empirical 
evidence indicating that biomedical research has been stifled from 
over-patenting.82 They argue that due to the expensive practice of de-
veloping drugs and biologics, the patents on genetic sequences are the 
necessary means to ensure the development of new drugs. 83 Because 
of the importance of biotechnology research tool patents, gene pat-
ents, and stem cell patents, proponents suggest that fear over the threat 
of a biotechnology anticommons is fueled by groups with a certain 
political agenda that is antithetical to patenting. 84 
Like human embryonic stem cells ("hESC") before them, human 
iPSCs (induced pluripotent stem cells) are a pioneering biotechnology 
invention. The world's first patent on iPSCs was granted in Japan to 
Shinya Yamanaka in 2008.85 In the United Kingdom, the world's sec-
ond patent on iPSCs was granted to iPierian Inc. in 2010.86 The first 
U.S. patent on iPSCs was granted in 2010 to Rudolf Jaenisch at Fate 
Therapeutics. 87 Like the broad claims obtained by Thomson/WARF 
for the early hESC patents, 88 if the claims in the pioneering iPSCs 
patents are interpreted too broadly, then iPSCs may face intellectual 
property rights obstacles that are similar to hESCs. Moreover, the 
stem cell community could be concerned about iPSCs because the 
licensing system by WARF has been frequently criticized as having a 
82 See Bailey, supra note 61 (''The good news is that evidence for a growing 
biomedical research anticommons that can stifle biomedical research is almost non-
existent."). 
83 Greenemeier, supra note 56 ("The biotech industry's stance has been that 
its work is expensive and important and needs to be licensed so that this work may 
continue."). 
84 See Kevin E. Noonan, This Just In - The Anti-commons Aren't So Tragic, 
PATENT Docs (Apr. 12, 2010, 11:59 PM), http://www.patentdocs.org/2010/04/this-
just-in-the-anticommons-arent-so-tragic.html (concluding that the main reason that 
fears of a tragedy of the anticommons exist, despite evidence to the contrary, is to 
"support a political agenda that is antithetical to patenting"). 
85 David Cyranoski, Japan Fast-Tracks Stem-Cell Patent, 455 NATURE 269, 
269 (2008) (Japanese patent No. 2008-131577, international application 
PCT/JP2006/324881 (filed June 12, 2006), publication number W0/2007/069666.). 
86 PR Newswire, First iPierian Patent for Induced Pluripotent Stem Cell 
Technology Granted by United Kingdom Intellectual Property Office, THE STREET 
(Jan. 28, 2010, 8:00 AM), http://www.thestreet.com/story/10668856/first-ipierian-
patent-for-induced-pluripotent-stem-cell-technology-granted-by-united-kingdom-
intellectual-property-office.html ("UK patent No. GB2450603 ... is the first patent 
protecting a fundamental method and utility of human iPSC technology that has been 
granted outside of Japan."). 
87 Ananyo Bhattacharya, First US Patent Issued for Induced Stem Cell Pro-
tocol, NATURE.COM (Feb. 4, 2010), 
http://blogs.nature.com/news/thegreatbeyond/2010/02/first_us_patent_issued_for_ind. 
html (citing U.S. Patent No. 7,682,828 (granted Mar. 23, 2010)). 
88 Plamer et al., supra note 65, at 13. 
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negative impact on the commercialization and development of 
hESCs.89 Therefore, the early iPSCs patents should be interpreted 
narrowly to include only what the inventors have achieved in light of 
the prior art, in order to avoid problems similar to those encountered 
by hESCs. 
III. MYTH OR REALITY NO. 3: PATENTS ON 
BIOTECHNOLOGY INVENTIONS HA VE DETRIMENTAL 
EFFECTS ON HUMAN HEALTH BY WAY OF DECREASING 
ACCESS TO DRUGS AND GENETIC TESTING. 
Over the past decade, few studies have analyzed the effect of bio-
technology patents on the cost, access, and development of genetic 
tests. One of these studies, conducted in 2003, concluded that re-
searchers had negative perceptions of the effects of patents on the 
cost, access, and development of genetic tests or data sharing. 90 In 
contrast, "most respondents felt that patents did not have an effect on 
the quality of testing."91 At the same time, patents and licenses were 
perceived as having "a significant effect on the ability of clinical labo-
ratories to develop and provide genetic tests."92 
The Secretary's Advisory Committee on Genetics, Health, and 
Society asked the Center for Genome Ethics, Law & Policy at Duke 
University to examine the effect of patents on genetic tests for ten 
clinical conditions: Alzheimer disease; breast cancer; Canavan dis-
ease; colon cancer; cystic fibrosis; hearing loss; hereditary hemo-
chromatosis; long QT syndrome; spinocerebellar ataxias; and Tay-
Sachs disease.93 The study revealed that patenting and licensing of 
genetic tests had "limited the ability of clinical laboratories to offer 
genetic testing."94 Based on its research of the literature and public 
comments, the study concluded that the existing patents could impede 
89 Caufield et al., supra note 68, at 485-86. 
90 Mildred K. Cho et al., Effects of Patents and Licenses on Provision of 
Clinical Genetic Testing Services, 5 JOURNAL OF MOLECULAR DIAGNOSTICS 
3,3 (2003). The study was based on a telephone survey of 122 clinical laboratory 
directors in the United States who perform DNA-based genetic tests. 
91 Id. 
92 Id. 
93 SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY, 
REVISED DRAFT REPORT ON GENE PA TENTS AND LICENSING PRACTICES AND THEIR 
IMPACT ON PATIENT ACCESS TO GENETIC TESTS 6-7 (2010), available at 
http://oba.od.nih.gov/oba/SACGHS/SACGHS%20Patents%20Report%20Approved% 
202-5-20010.pdf. The study focused on analyzing multiplex testing, where a single 
test could simultaneously test for multiple genetic markers. Id. at 44. 
94 Id. at 35 ("[T]he ability of clinical laboratories to offer genetic testing ... 
can affect patient access, the quality of testing, and efforts to innovate."). 
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85 David Cyranoski, Japan Fast-Tracks Stem-Cell Patent, 455 NATURE 269, 
269 (2008) (Japanese patent No. 2008-131577, international application 
PCT/JP2006/324881 (filed June 12, 2006), publication number W0/2007/069666.). 
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html (citing U.S. Patent No. 7,682,828 (granted Mar. 23, 2010)). 
88 Plamer et al., supra note 65, at 13. 
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89 Caufield et al., supra note 68, at 485-86. 
90 Mildred K. Cho et al., Effects of Patents and Licenses on Provision of 
Clinical Genetic Testing Services, 5 JOURNAL OF MOLECULAR DIAGNOSTICS 
3,3 (2003). The study was based on a telephone survey of 122 clinical laboratory 
directors in the United States who perform DNA-based genetic tests. 
91 Id. 
92 Id. 
93 SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY, 
REVISED DRAFT REPORT ON GENE PATENTS AND LICENSING PRACTICES AND THEIR 
IMPACT ON PATIENT ACCESS TO GENETIC TESTS 6-7 (2010), available at 
http://oba.od.nih.gov/oba/SACGHS/SACGHS%20Patents%20Report%20Approved% 
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94 Id. at 35 ("[T]he ability of clinical laboratories to offer genetic testing ... 
can affect patient access, the quality of testing, and efforts to innovate."). 
82 JOURNAL OF LAW, TECHNOLOGY & THE INTERNET [Vol. 3:1 
innovation on future genetic testing.95 Specifically, the thicket of gene 
patents presents many challenges-most notably, the high cost of li-
censes and royalty fees, as well as the risk of litigation-for a labora-
tory to attempt to develop a multiplex test.96 Due to the fear of litiga-
tion, clinicians were not reporting the results of patent-protected genes 
in their multiplex tests, severely inhibiting the tests' effectiveness.97 
It is difficult to invent around a substantial number of patents re-
lating to genetic testing.98 Moreover, a recent reappraisal of human 
gene patents and genetic testing in Europe considered the potential for 
gene patents to affect the provision of genetic testing. 99 There could 
be a considerable effect on the delivery of genetic tests to patients.100 
The proponents of biotechnology patents believe that patents on 
biotechnology inventions foster the development of new medicines.101 
Important gene-based drugs (such as insulin, erythropoietin, and 
growth factor VIII) have enjoyed protection as patents while simulta-
neously providing medical benefits.102 Thus, patents and patent li-
censes can be viewed as simply part of the cost of doing business. 
Society relies largely on private entities to invest in developing new 
genetic research-based treatments and diagnostics. It costs an esti-
mated $1 billion to discover a new drug. 103 As an incentive to conduct 
R & D, biopharma will want to continue to require some degree of 
exclusivity over these technologies. How else can companies recover 
their investment in R & D? 
In reality, one is hard-pressed to provide evidence with respect to 
the types of genetic tests that are unavailable due to patents. Further-
more, according to the USPTO' s utility guidelines, "whole genome" 
95 Id. at 50 ("[T]he numerous existing patent claims on genes are already 
affecting the use, if not the development, of multiplex tests in that clinicians are not 
reporting the results for patent-protected genes in multiplex tests for fear of inviting a 
lawsuit."). The study cited Myriad's patents and the Canavan disease patents as ex-
amples of when laboratories stopped giving genetic tests due to the enforcement of 
those patents. Id. at 36. 
96 Id. at 48. 
97 Id. at 50. 
98 Isabelle Huys et al., Legal Uncertainty in the Area of Genetic Diagnostic 
Testing, 27 NATURE BIOTECHNOLOGY 903,903 (2009) (citing commentators observa-
tion that "blocking patents" or "patent thickets" are "difficult or impossible to cir-
cumvent"). 
99 Naomi Hawkins, Human Gene Patents and Genetic Testing in Europe: A 
Reappraisal, 7 SCRIPTED 453 (2010). 
100 See Id. at 473 ("Patents on human genes could have a negative effect on 
the translation of basic biomedical research into clinical application."). 
101 Cho, supra note 90, at 7. 
102 Andrews, supra note 17, at 66. 
103 J.A. DiMasi et al., The Price of Innovation: New Estimates of Drug Devel-
opment Costs, 22 J. HEALTH ECON. 151, 181 (2003). 
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sequencing would not infringe patent claims on individual genes, be-
cause the gene would not be isolated. Thus, the real issues revolve 
around the costs of the tests, and to a lesser degree the restrictive li-
censing practices. Patient access may be affected due to a patent 
holder's exorbitant royalty fee, thus increasing the transactional costs 
for testing. 104 
IV. MYTH OR REALITY NO. 4: PATENTING HUMAN 
GENES AND STEM CELLS IS TANTAMOUNT TO 
PATENTING LIFE AND IS THEREFORE INTRINSICALLY 
IMMORAL. 
Ethics and morality are intertwined with DNA, genes, and embry-
onic stem cells. Ethical judgments about patenting human genes-
such as views that patenting genes amounts to a form of modem slav-
ery, or that patenting creates monopolies on living organisms-are 
abundant. Gene patents have increasingly faced public scrutiny, often 
from people who lack the legal and technical background to fully un-
derstand genetics and the complexities of the patent. process.105 This 
lack of understanding has led them to make emotional and radical 
one-sided arguments. 106 
Furthermore, stem cells theoretically raise the issue of the pat-
entability of living organisms, particularly humans. At least one of the 
techniques (embryonic cloning), whereby cells are removed from an 
embryo, already allows the creation of a viable adult. 107 Hence, 
moral considerations are common to the policies excluding patentabil-
104 Illustrative examples of restrictive licensing practices include the BRCA 
tests for ovarian and breast cancer (extensively discussed elsewhere) and the Canavan 
disease tests. The ASP A gene and mutated sequences associated with Canavan dis-
ease were discovered and patented in 1997 by researchers at Miami Children's Hospi-
tal (MCH). LINDA L. McCABE & EDWARD R. B. McCABE, DNA: PROMISE AND 
PERIL 155 (Univ. of Cal. Press 2008). After a litigation and subsequent settlement, 
MCH continued to enforce "royalty-based genetic testing for certain licensed labora-
tories." Id. at 156. However, the agreement permitted academic institutions to engage 
in royalty-free research of Canavan disease after 2003. Id. (citing "royalty-free re-
search by institutions, doctors, and scientists searching for a cure"). 
105 See, e.g., Genes and patents: More harm than good?, THE ECONOMIST, 
Apr. 17, 2010. 
106 See generally MICHAEL CRICHTON, JURASSIC p ARK (Ballantine Books 
1991) (recounting the mayhem that results in a world where genetic engineers resur-
rect dinosaurs); MARY SHELLEY, FRANKENSTEIN; OR, THE MODERN PROMETHEUS (Sig-
net Classic 3d. ed. 1983) (1831) (wherein the diabolical tinkering of the prototypical 
"mad scientist" unleashes a nightmarish specter on unsuspecting villagers). 
107 See Kathi E. Hanna, Cloning/Embryonic Stem Cells, NATIONAL 
INSTITUTES OF HEALTH: NATIONAL HUMAN GENOME RESEARCH INSTITUTE (April 
2006), http://www.genome.gov/10004765. 
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96 Id. at 48. 
97 Id. at 50. 
98 Isabelle Huys et al., Legal Uncertainty in the Area of Genetic Diagnostic 
Testing, 27 NATURE BIOTECHNOLOGY 903,903 (2009) (citing commentators observa-
tion that "blocking patents" or "patent thickets" are "difficult or impossible to cir-
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99 Naomi Hawkins, Human Gene Patents and Genetic Testing in Europe: A 
Reappraisal, 7 SCRIPTED 453 (2010). 
100 See Id. at 473 ("Patents on human genes could have a negative effect on 
the translation of basic biomedical research into clinical application."). 
101 Cho, supra note 90, at 7. 
102 Andrews, supra note 17, at 66. 
103 J.A. DiMasi et al., The Price of Innovation: New Estimates of Drug Devel-
opment Costs, 22 J. HEALTH ECON. 151, 181 (2003). 
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ity of hESC - and they relate to the potential of developing into a ma-
ture human being. In 2001, President George W. Bush banned the 
creation of new hESC lines with federal funding. 108 During the Bush 
administration, scientists were forced to explore alternatives to hESCs 
due to moral and policy concerns. 109 
The use of embryonic stem cells in research is highly controver-
sial. As discussed below, ethical judgments about the generation of 
embryonic stem cells and their use in research and therapies are typi-
cally a function of the status accorded to the embryo. Some attempt to 
frame the question in terms of the definition of life, whereby the cen-
tral question becomes: is the human embryo a person or a piece of 
property? Some feel that an embryo is a human being. They contend 
that it is unethical to do anything to an embryo that should not be 
done to a person. Others view the embryo as nothing more than a ball 
of cells. They accord it a treatment similar to tissues and organs used 
in transplantation. 
Broad global, ethical guidelines regulate the patenting of genetic 
inventions. The TRIPS Agreements allows each country the right to 
refuse patents based on the morality laws of that country. 110 Indeed, 
moral considerations are common to the policies excluding patentabil-
ity of genetically engineered organisms.111 Technical grounds of pat-
entability also act as important safeguards of the public interest.112 
Yet technological advances reframe the morality questions. 
Some European countries have banned research and patents on 
hESCs because they are parts of a human body .113 European patent 
law contains a narrowly construed morality test, which is formally and 
explicitly embedded in patent law; European patents are not granted 
for inventions for which the commercial exploitation of those inven-
108 See Bush's Address on Federal Financing for Research with Embryonic 
Stem Cells, N.Y. TIMES, Aug. 10, 2001, at A16. 
109 See Thomas Scott & Renee A. Reijo Pera, The Road to Pluripotence: The 
Research Response to the Embryonic Stem Cell Debate, 17 HUMAN MOLECULAR 
GENETICS R3, R3-R7 (2008); Exec. Order No. 13435, 72 Fed. Reg. 34,591 (June 20, 
2007). 
110 Agreement on Trade-Related Aspects of Intellectual Property Rights art. 
27.1, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organiza-
tion, Annex IC, 1869 U.N.T.S. 299. 
111 Cf Diamond v. Chak:rabarty, 447 U.S. 303, 317 (1980) (Stating that dis-
cussion about patentable subject matter necessarily "involves the balancing of com-
peting values and interests, which in our democratic system is the business of elected 
representatives."). 
112 See Andrews, supra note 17, at 70-72. 
113 Todd N. Spalding & Michele M. Simkin, How Will Patents Impact the 
Commercialization of Stem Cell Therapeutics?, 19 No. 1 INTELL. PROP. & TECH. L. J. 
7, 7 (2007). 
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tions would be contrary to ordre public or morality. 114 However, such 
exploitation is not deemed to be contrary merely because it is prohib-
ited by law or regulation in some or all of the European Patent Con-
. . 115 
vent10n contractmg states. 
In the U.S., hESCs are patentable subject matter. Under 35 U.S.C. 
§ 101, "whoever invents or discovers any new and useful process, 
machine, manufacture, or composition of matter, or any new and use-
ful improvement thereof, may obtain a patent."116 Even though hESCs 
are derived from embryos, the fact that they are living matter does not 
preclude them from patentability. Since hESCs are isolated from the 
inner cell mass of embryos, they are altered by man and do not occur 
naturally; thus, they are patentable. The USPTO has not deemed 
hESCs to be the equivalent of a human being for patenting pur-
poses.117 In general, in the U.S., morality seems to have played little 
role in biotechnology patenting. In the context of hESCs, the medical 
benefits could help counterbalance the moral core of the opponents. 
However, claims about the sanctity of embryonic life are less compel-
ling because images of sick children, suffering adults and grieving 
relatives often override and displace the pro-life images of embryos 
that have had such a powerful impact on the abortion debate.118 
In reality, the empirical data does not support the perceived con-
cerns and expressed fears. The patenting of a single human gene has 
nothing to do with patenting life. It is scientifically inaccurate to as-
cribe genes with a special role, just as if they were life itself.119 It is 
also legally inaccurate to equate genes with life. In Amgen v. Chugai, 
the gene was defined as "a chemical compound, albeit a complex one 
•••• "
120 Yet, although a gene was first awarded patent protection in 
114 Id. 
115 European Patent Convention, art. 53(a), Dec. 13, 2007, available 
athttp://documents.epo.org/projects/babylon/eponet.nsf/0/7bacb229e032863dc12577e 
c004ada98/$FILE/EPC_14th_edition.pdf. Case law has established that the exclusion 
only concerns extreme cases that are universally regarded as abhorrent, and European 
patents have been granted for the majority of biotechnology achievements. 
116 35 u.s.c. § 101 (2010). 
117 Spalding & Simkin, supra at Note 113, at 7 (The USPTO "has not deemed 
embryonic stem cells to be the equivalent of a human being."). 
118 Janet L. Dolgin, Embryonic Discourse: Abortion, Stem Cells and Cloning, 
31 FLA. ST. U. L. REV. 101, 158 (2003) ("The images produced by such narratives can 
provide alternatives to and thus displace pro-life images of fetuses and embryos. In 
the face of images of embryos-as-salvation for individual, sick children and disabled 
heroes, assertions about embryonic personhood may pale."). 
119 Cf Helen Pearson, Genetics: what is a gene?, 441NATURE398 (2006). 
120 Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991). 
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tions would be contrary to ordre public or morality.114 However, such 
exploitation is not deemed to be contrary merely because it is prohib-
ited by law or regulation in some or all of the European Patent Con-
. . 115 
vent10n contractmg states. 
In the U.S., hESCs are patentable subject matter. Under 35 U.S.C. 
§ 101, "whoever invents or discovers any new and useful process, 
machine, manufacture, or composition of matter, or any new and use-
ful improvement thereof, may obtain a patent."116 Even though hESCs 
are derived from embryos, the fact that they are living matter does not 
preclude them from patentability. Since hESCs are isolated from the 
inner cell mass of embryos, they are altered by man and do not occur 
naturally; thus, they are patentable. The USPTO has not deemed 
hESCs to be the equivalent of a human being for patenting pur-
poses.117 In general, in the U.S., morality seems to have played little 
role in biotechnology patenting. In the context of hESCs, the medical 
benefits could help counterbalance the moral core of the opponents. 
However, claims about the sanctity of embryonic life are less compel-
ling because images of sick children, suffering adults and grieving 
relatives often override and displace the pro-life images of embryos 
that have had such a powerful impact on the abortion debate.118 
In reality, the empirical data does not support the perceived con-
cerns and expressed fears. The patenting of a single human gene has 
nothing to do with patenting life. It is scientifically inaccurate to as-
cribe genes with a special role, just as if they were life itself. 119 It is 
also legally inaccurate to equate genes with life. In Amgen v. Chugai, 
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.... "
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116 35 u.s.c. § 101 (2010). 
117 Spalding & Simkin, supra at Note 113, at 7 (The USPTO "has not deemed 
embryonic stem cells to be the equivalent of a human being."). 
118 Janet L. Dolgin, Embryonic Discourse: Abortion, Stem Cells and Cloning, 
31 FLA. ST. U. L. REV. 101, 158 (2003) ("The images produced by such narratives can 
provide alternatives to and thus displace pro-life images of fetuses and embryos. In 
the face of images of embryos-as-salvation for individual, sick children and disabled 
heroes, assertions about embryonic personhood may pale."). 
119 Cf. Helen Pearson, Genetics: what is a gene?, 441NATURE398 (2006). 
120 Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991). 
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1982, 121 the debate regarding patenting genes is still continuing and 
in the U.S. reached a new peak in the Myriad case.122 
The ethical concerns that accompany hESCs are not at issue for 
iPSCs. For example, one method used to create genetically matched 
patient-specific hESCs is through somatic cell nuclear transfer 
(SCNT).123 However, there are unknown risks, and many legal and 
ethical problems associated with oocyte donation and SCNT, as 
"SCNT is commonly used to produce clones."124 An oocyte contain-
ing "DNA from an adult cell could in theory be implanted into a 
woman's uterus and come to term as an actual cloned human."125 
Thus, there exists strong opposition to the use of SCNT to generate 
hESCs. Human cloning is not just a matter of ethical debate; it is ille-
gal.126 
In contrast to hESCs, iPSCs are derived from adult cells, not from 
embryos. 127 Therefore, creating iPSCs does not require oocyte dona-
tion.128 Unlike deriving hESCs from SCNT, there are ample adult 
cells (such as skin), from which researchers can derive iPSCs.129 In 
addition, iPSCs have the same benefits as hESCs derived from 
SCNT .130 Similar to hESCs, iPSCs are patentable subject matter in the 
U.S. under 35 U.S.C. § 101. They are manipulated by man, repro-
121 U.S. Patent No. 4,363,877 (filed Apr. 19, 1978). 
122 Ass'n for Molecular Pathology v. USPTO, 653 F.3d 1329 (Fed. Cir. 
2011). 
123 See George Q. Daley, Towards the Generation of Patient-Specific Pluripo-
tent Stem Cells for Combined Gene and Cell Therapy of Hematologic Disorders, 
HEMATOLOGY 17, 18 (2007) (discussing the history of SCNT as used for modeling 
disease and its promise in creating hESCs). 
124 Jonathan M.W. Slack, Stem Cell: Somatic Cell Nuclear Transfer, 
ENCYCLOPEDIA BRITANNICA (Dec. 6, 2008), 
http://www.britannica.com/EBchecked/topic/565 211/stem-cell. 
12s Id. 
126 Id. ("[T]he cloning of humans is currently illegal throughout the world 
. . .. "). 
127 Jonathan M.W. Slack, Stem Cell: Induced Pluripotent Stem Cells, Ency-
clopedia Britannica (Dec. 6, 2008), 
http://www.britannica.com/EBchecked/topic/565211/stem-cell (explaining the proc-
ess of using adult cells in iPSCs). 
12s Id. 
129 See Sayandip Mukherjee, Induced Pluripotent Stem Cells: A New Hope or 
a New Controversy?, 0PTICON1826, Autumn 2008, at 3-4, available at 
http://www.ucl.ac.uk/opticon1826/archive/Issue5/Article_BM_Mukherjee.pdf (de-
scribing the discovery of and further research into iPSCs derived from adult human 
fibroblasts). 
130 See id. (summarizing the results of iPSC testing). 
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grammed to behave as stem cells, and should thus be considered a 
composition of matter or a manufacture.131 
There would seem to be less moral opposition to iPSC patentabil-
ity and to the similar new discoveries related to reprogramming hu-
man adult cells to behave much like hESCs. Yet the philosophical 
question remains: will opponents of embryo research embrace the 
concept of using iPSCs or the concept of reprogramming cells to their 
embryonic state? It might be 'possible to use an induced pluripotent 
stem cell or a reprogrammed cell to create an entire person, in the 
same way that an implanted embryo can develop into a person. Given 
this possibility, will people who believe embryos have the same moral 
value as persons (and thus should not be used for experimentation), 
believe that iPSCs (and skin cells that are used for derivation iPSCs) 
or reprogrammed cells should also not be used for experimentation? 
There is a substantial difference between an embryo, embryonic stem 
cell, induced pluripotent stem cell and skin cell, but not everyone who 
favors the protection of embryos thinks this difference is dispositive 
of the question.132 
The prudency of allowing the USPTO to make moral assessments 
is questionable. Patent law is not the appropriate vehicle for regulation 
of technology based on moral or ethical concerns.133 Appropriate 
legislation or regulatory vehicles, such as research regulation, should 
be used instead. 134 
V. SOLUTIONS FOR DEMYTHIFICATION THROUGH 
PATENT LAW AND POLICY ALTERNATIVES 
Based on empirical data from a variety of sources, the perceptions 
and fears over cloning humans, the generation of human-animal chi-
meras, the tragedy of the anticommons, and the other evils within the 
biotechnology community all seem to be largely overestimated.135 
131 35 U.S.C. § 101 (2010) ("Whoever invents or discovers any new and 
useful .... manufacture, or composition of matter, or any new and useful improve-
ment thereof, may obtain a patent therefor .... ") . 
132 When it was demonstrated that it is possible to use single cells from 8-cell 
embryos to create cell lines, some opponents of embryo research (including Senator 
Sam Brownback) protested on the ground that the single cell in question deserved 
protection. See Russell Korobkin, Exciting Stem Cell News, THE VOLOKH 
CONSPIRACY (Nov. 20, 2007, 2:49 PM), http://volokh.com/posts/l 195588155.shtml. 
133 See Bratislav Stankovic, Patenting the Minotaur, 12 RICH. J. L. & TECH. 5, 
35 (2005), available at http://law.richmond.edu/jolt/v12i2/article5.pdf (discussing 
biotechnology critics' attack on patent law, and how the proper forum for these critics 
is the Legislature). 
134 Id. 
135 See, e.g., Bailey, supra note 61; Mills & Tereskerz, supra note 79. 
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The prudency of allowing the USPTO to make moral assessments 
is questionable. Patent law is not the appropriate vehicle for regulation 
of technology based on moral or ethical concerns.133 Appropriate 
legislation or regulatory vehicles, such as research regulation, should 
be used instead. 134 
V. SOLUTIONS FOR DEMYTHIFICATION THROUGH 
PATENT LAW AND POLICY ALTERNATIVES 
Based on empirical data from a variety of sources, the perceptions 
and fears over cloning humans, the generation of human-animal chi-
meras, the tragedy of the anticommons, and the other evils within the 
biotechnology community all seem to be largely overestimated.135 
131 35 U.S.C. § 101 (2010) ("Whoever invents or discovers any new and 
useful .... manufacture, or composition of matter, or any new and useful improve-
ment thereof, may obtain a patent therefor .... ") . 
132 When it was demonstrated that it is possible to use single cells from 8-cell 
embryos to create cell lines, some opponents of embryo research (including Senator 
Sam Brownback) protested on the ground that the single cell in question deserved 
protection. See Russell Korobkin, Exciting Stem Cell News, THE VoLOKH 
CONSPIRACY (Nov. 20, 2007, 2:49 PM), http://volokh.com/posts/l 195588155.shtml. 
133 See Bratislav Stankovic, Patenting the Minotaur, 12 RICH. J. L. & TECH. 5, 
35 (2005), available at http://law.richmond.edu/jolt/v12i2/article5.pdf (discussing 
biotechnology critics' attack on patent law, and how the proper forum for these critics 
is the Legislature). 
134 Id. 
135 See, e.g., Bailey, supra note 61; Mills & Tereskerz, supra note 79. 
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While there is little substantiated evidence to support the notion that 
patents on basic research tools, genes, and stem cells are the reasons 
scientists decided to abandon downstream research, some empirical 
data establishes that gene patents impede innovation on genetic test-
ing.136 Nevertheless, various legal and policy solutions could be 
adopted to prevent an escalation of the myths, and to prevent antici-
pated problems. 
Some aspects of demythification can be achieved through imple-
. mentation of novel ideas for creative patentability and licensing of 
biotech/genetic inventions. Historically, researchers have managed to 
limit the negative effects of research tool patents by implementing a 
number of working solutions; successful strategies included ignoring 
patents, going offshore, creating public databases, and challenging 
patents in courts.137 Before becoming creative in pursuit of working 
solutions, the researchers would typically identify the relevant patents 
and then attempt to obtain a license to use the patented technology 
from the various biotech firms. 138 IT negotiations broke down, re-
searchers would either attempt to invent around the existing patents or 
implement a working solution.139 Indeed, research and commercializa-
tion in the biomedical sciences continues despite the proliferation of 
patents on upstream biotechnologies. 
The voluntary formation of patent pools by biotech firms and ge-
netic testing companies could alleviate some of the negative effects 
associated with the enforcement of patents on basic research tools and 
other fundamental biotechnology inventions. 140 However, this may be 
an unlikely scenario because the biotech community may be unwilling 
136 This is precisely what happened with the Canavan patents owned by 
MCH. See McCabe & McCabe, supra note 104, at 154-56. 
137 Walsh et al., supra note 69, at 324. 
138 See Id. at 322 (examining the practice of contracting for research tool 
patent licenses, specifically in the drug industry). 
139 Id. at 314-17. Researchers noted that identifying the relevant patents in a 
given field is both costly and time consuming, but identifying patents is expected due 
to the increased number of patents granted for research tools. The study reported that 
over half of the interviewees agreed that the patent landscape had become more com-
plex, but interestingly, that the actual number of patents needed to be cleared for a 
given project is often substantially smaller than one would assume. For example, a 
1998 study examining the method of putting hemoglobin in maize discovered that out 
of 500 patents reviewed on the subject matter, only 13 patents were relevant. Id. at 
294. 
140 A patent pool is an agreement between two or more patent owners to li-
cense their patents as a package to one another, as well as third parties willing to pay 
the associated royalties. See SECRETARY'S .ADVISORY COMMITTEE ON GENETICS, 
HEALTH, AND SOCIETY, supra note 93, at 50-54 (discussing the use of patent pools as 
an approach to solve "patent thickets"). 
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to form patent pools for genetic testing, especially when companies 
can make higher profits licensing their own tests individually.141 So-
cietal or government pressure may be necessary to create a patent 
pool, particularly when patent exclusivity is being used contrary to the 
public interest. 142 
March-in rights already exist in international and U.S. patent law: 
the U.S. government can force non-exclusive license if research was 
supported by government funds. 143 One policy alternative is to lobby 
Congress to change biotech patenting legislation to make it subject to 
a public interest provision in addition to those already outlined in 37 
C.F.R. § 401.14. For example, if a patent was obtained using federal 
funds (such as from the National Institute of Health ("NIH")), and 
there is a public outcry that the patent-holder is enforcing its patent 
contrary to the public interest, then the NIH would be able to force a 
compulsory license at reasonable terms. The public interest provision 
could be somewhat similar to Article 53(a) of the European Patent 
Convention, which prohibits patents for "inventions the exploitation 
of which would be contrary to [public order] or morality .... "144 This 
type of provision would not be an outright ban on research tool pat-
ents, but rather 'Yould allow the federal funding agency (e.g., NIH) the 
ability investigate the issue. IT the NIH determines that a patent 
holder's enforcement of a certain patent is contrary to the public inter-
est, the NIH would draft a reasonable licensing agreement. This would 
eliminate transaction costs to laboratories because there would be no 
negotiation of licensing terms. 
Patent law already provides a claim scope gatekeeping mecha-
nism, which can be illustrated with patents on stem cell inventions. 
Even though stem cell intellectual property is complex, due to moral, 
technical, and legal factors, 145 iPSCs offer a promising alternative 
with decreased ethical barriers. To prevent iPSC patents from impact-
ing downstream technological advances in stem cell research and 
141 Id. Additionally, one patent holder can hold out from entering a patent 
pool if they own a patent covering an important claim or gene and exploit it for their 
own purposes. Id. Furthermore, if a company owns all the patents related to a gene 
mutation relevant for testing, there would be less of an incentive to join a patent pool. 
Id. 
142 The Canavan disease and genetic testing story is informative. Due to the 
mounted response by the Canavan organizations and the Jewish community against 
MCH' s methods of enforcing its ASPA gene patent, MCH subsequently changed its 
practices. The same change in patent enforcement could also be possible with other 
patent holders through formation of patent pools and a change in legislation. See 
McCabe & McCabe, supra note 104, at 155-56. 
143 37 C.F.R. § 401.14 (2004). 
144 European Patent Convention, supra note 115, at art. 53(a). 
145 Plomer et al., supra note 65. 
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commercialization, examiners and courts should be careful to allow 
iPSC patent claims to be only as broad as the specification allows in 
light of the breadth of the prior art. Pioneer inventors deserve exclu-
sive rights for their discovery, but not at the expense of hindering fu-
ture innovation and research. 146 
Biotech inventors and patent prosecutors must use creative patent 
claim drafting and emphasize the differences between isolated and 
natural DNA. Arguably, isolated DNA may be patentable as a cultural 
artifact that has no equivalent to naturally occurring DNA in vivo. 
Isolated DNA is a unique result of modifying the DNA by placing it 
in an appropriate medium (e.g., a polypeptide-encoding polynucleo-
tide that does not have the naturally occurring chemical modifications, 
methyl groups, amines, metal ions, etc.). Isolated cDNA is not found 
in nature. 147 
An argument could also be made for patentability of a product-by-
process: to qualify for patentability, an element from the human body 
must be the product of technical processes which have identified, pu-
rified, and characterized the product outside of the human body. 
Again, such techniques cannot be found in nature. In addition, isolated 
stem cells may be patentable as cultural artifacts. If used for deriva-
tion of an embryonic stem cell line, blastocysts are explanted into a 
culture medium and cultured in vitro.148 This effectively results in 
selection for in vitro survival; pluripotency is a useful side product of 
the procedure.149 Consequences in proof are: different chromatin con-
figurations; different epigenetic characteristics; disturbed methylation; 
loss of imprinting; and significantly higher incidence of Beckwith-
Widemann syndrome in IVF babies, an imprinting disorder caused by 
LOI of Igf2 and other imprinted genes.150 This results in the creation 
of a novel cell type; an isolated embryonic stem cell represents a cul-
tural artifact that has no equivalent to cells of the embryo. 151 
The controversies that surround the issuance of patents on genetic 
inventions stem from conflicting social policies that utilize the patent 
system as a vehicle of expression. Yet the debate surrounding the is-
sue of patentability of biotechnology inventions ultimately boils down 
146 Robert P. Merges & Richard R. Nelson, On the Complex Economics of 
Patent Scope, 90 COLUM. L. REV. 839, 908 (1990). 
147 See Ass'n for Molecular Pathology v. USPTO, 702 F.Supp.2d 181, 196 
(S.D.N.Y. 2010) (explaining DNA extraction). 
148 Mats G. Hansson et al., Isolated Stem Cells-Patentable as Cultural Arti-
facts?, 25 STEM CELLS 1507, 1507 (2007) (explaining the process of creating novel 
stem cells through blastocyst culturing). 
149 Id. at 1508. 
150 Id. 
151 Id. 
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to the same thing: should we be patenting something so fundamental? 
From a legal point of view, the answer is most likely "yes." Multiple 
precedents exist for patentability of other revolutionary technologies 
in the life sciences. These include growing cells and tissues in vitro, 152 
recombinant DNA methods, 153 and PCR. 154 Patent law is not the right 
forum for balancing biotechnology discoveries with ethical, moral, 
and religious beliefs, and should not be used for prohibiting activity 
that may be regarded as objectionable on grounds unrelated to patent 
law.155 Various doctrines in patent law (subject matter, utility, written 
description requirement, enablement requirement, person of ordinary 
skill in the art, equivalents, etc.) provide the judiciary with ample 
tools to tailor patent law to the needs of specific subject matter. If 
deemed appropriate and necessary, sui generis patent categories for 
(some fundamental) biotechnology inventions may be created. 
"[P]ublic policy, including patent law, should encourage inventive 
rivalry, and not hinder it."156 It would be inappropriate to deny pat-
entability of inventions on the basis of speculative future risks. The 
biotechnology patent may appear selfish-just like the gene it may 
correspond to-but governments would be hypocritical to encourage 
innovation, invention, and patenting, while at the same prohibiting 
controversial biotechnology research. 
152 T" l issue cu ture propagator and method. U.S. Patent No. 3,407,120 (filed 
Dec. 23, 1965). 
153 Recombinant DNA method. U.S. Patent No. 5,747,308 (filed Feb. 7 
1995). ' 
154 p 
155 
CR method. U.S._ Patent No. 7,101,663 (filed Mar. 4, 2002). 
Regretfully, other issues such as abortion keep influencing the policy. For 
example, in 2004 Rep. Dave Weldon (R-FL) sponsored an amendment to the Con-
solidated Appropriations Act of 2004, aimed at preventing the use of federal funds to 
issue patents on human organisms, including embryos and fetuses. The vague, 
overly-broad language did not define "human organism" and it could have precluded 
patenting of many human-derived biotechnology inventions. 149 CONG. REc. E2417 
(daily ed. Nov. 22, 2003) (statement of Rep. Weldon). 
156 Merges & Nelson, supra note 146, at 908. 
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ARE TECHNICAL DIFFICULTIES AT 
THE SUPREME COURT CAUSING A 
''DISREGARD OF DUTY''? 
Mark Grabowski1 
ABSTRACT 
Recent U.S. Supreme Court cases involving technology-related is-
sues indicate that several Justices are embarrassingly ignorant about 
computing and communication methods that many Americans take for 
granted. Indeed, some Justices admit they are behind the times. Yet, 
as members of the nation's highest court, they are increasingly asked 
to set legal precedents about these very technologies. The implications 
are profound for U.S. media law because, with the advent of the Digi-
tal Age, speech and expression have become intertwined with tech-
nology. The article argues that it is crucial for our most important 
decision-makers to keep pace with the times; otherwise, they may 
make poor legal decisions or avoid hearing important cases because 
they do not grasp the issues involved. In fact, such missteps may al-
ready be occurring. A few possible solutions are offered. 
INTRODUCTION 
If you are in America and not yet acquainted with cell phones, 
computers and the Internet, you must have spent the past decade under 
a rock-or be a member of the United States Supreme Court. Supreme 
Court Justices lately have displayed a startling level of ignorance 
about computing and communication methods that many Americans 
take for granted. Justice Clarence Thomas "generally characterizes the 
1 Mark Grabowski is an assistant professor of communication at Adelphi 
University, where he teaches media law and new media. He also writes a column on 
legal affairs for AOL News, the third-most visited news website in the nation. He 
holds a B.A. from Case Western Reserve University and a J.D. from Georgetown 
Law. Special thanks to David R. Dewberry, Pallavi Guniganti, Chaitali P. Kapadia, 
and the staff and peer reviewer of the Journal of Technology, Law & Internet for their 
helpful feedback. Attempts were made to contact Supreme Court Justices and officials 
for comment, but they did not return calls. 
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